View ValuationCorentec 将来の成長Future 基準チェック /06現在、 Corentecの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長43.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updates分析記事 • Apr 01Shareholders Can Be Confident That Corentec's (KOSDAQ:104540) Earnings Are High QualityThe subdued stock price reaction suggests that Corentec Co., Ltd.'s ( KOSDAQ:104540 ) strong earnings didn't offer any...お知らせ • Mar 13Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩5,490, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 50% over the past three years.分析記事 • Dec 23There's No Escaping Corentec Co., Ltd.'s (KOSDAQ:104540) Muted Revenues Despite A 31% Share Price RiseCorentec Co., Ltd. ( KOSDAQ:104540 ) shareholders would be excited to see that the share price has had a great month...New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩87.1b market cap, or US$59.2m).Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩6,810, the stock trades at a trailing P/E ratio of 58.8x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total loss to shareholders of 31% over the past three years.分析記事 • Nov 05Investors Aren't Buying Corentec Co., Ltd.'s (KOSDAQ:104540) RevenuesCorentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...New Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩75.3b market cap, or US$54.2m).分析記事 • Apr 10Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩79.0b market cap, or US$53.9m).お知らせ • Mar 13Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South Korea分析記事 • Jan 06Lacklustre Performance Is Driving Corentec Co., Ltd.'s (KOSDAQ:104540) Low P/SCorentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩70.8b market cap, or US$49.3m).Reported Earnings • Nov 20Third quarter 2024 earnings released: ₩70.00 loss per share (vs ₩113 profit in 3Q 2023)Third quarter 2024 results: ₩70.00 loss per share (down from ₩113 profit in 3Q 2023). Revenue: ₩22.0b (down 7.0% from 3Q 2023). Net loss: ₩897.3m (down 162% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.分析記事 • Nov 14Corentec's (KOSDAQ:104540) Returns On Capital Are Heading HigherWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Sep 10Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 62% over the past three years.分析記事 • May 28Corentec Co., Ltd.'s (KOSDAQ:104540) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 35.4x Corentec Co., Ltd. ( KOSDAQ:104540 ) may be sending very bearish...New Risk • May 25New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Market cap is less than US$100m (₩107.4b market cap, or US$78.7m).New Risk • Apr 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.0b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩132.0b market cap, or US$97.8m).New Risk • Oct 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩135.1b market cap, or US$99.5m).お知らせ • May 18Corentec Co., Ltd. announced that it has received KRW 1.19999236 billion in fundingOn May 17, 2023, Corentec Co., Ltd. closed the transaction.お知らせ • May 11Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc.Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc. for KRW 7.2 billion on May 9, 2023. Corentec will acquire 92.34 million shares in Woosung Pharma. Corentec Co., Ltd. (KOSDAQ:A104540) completed the acquisition of 80% stake in Woosung Pharma Inc. on May 9, 2023.お知らせ • May 10Corentec Co., Ltd. announced that it expects to receive KRW 1.19999236 billion in fundingCorentec Co., Ltd announced a private placement of 102,214 common shares of par value KRW 500 per share at an issue price of KRW 11,740 per share for gross proceeds of KRW 1,200,000,000 on May 9, 2023. The transaction will include participation from new investor Hwan-woo Cho. The company will issue securities through third party allotment method. All securities to be issued will be subject to a lock-up period of one year. The transaction has been approved by the board of directors of the company and is expected to close on May 17, 2023.お知らせ • Feb 08Corentec Appoints Michael Son as Executive Vice PresidentCorentec has re-hired Michael Son to lead its sales and business development operations in the Americas, as Executive Vice President. Son will be responsible for pricing strategies, negotiations, hiring, and P&L, and will report to Corentec’s three Co-CEO’s, the Sun Brothers. Son, who was previously with Corentec from 2011 to 2015 as Vice President of Sales, brings more than 25 years of medical device sales experience where he worked with both large and small/start-up orthopedic companies in the European, Asia-pacific, U.S. and South America markets. Son is a highly strategic and influential medical device sales leader who will play an important role in building and strengthening relations between Corentec’s Korean operations and the Americas. Son holds a Bachelor of Arts Degree from University of Waterloo in Ontario, Canada, and is a graduate of the Executive Business Management program and National University of Singapore.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 17First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: ₩10.6b (up 6.7% from 1Q 2020). Net income: ₩953.1m (up 1.1% from 1Q 2020). Profit margin: 9.0% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.分析記事 • May 09These 4 Measures Indicate That Corentec (KOSDAQ:104540) Is Using Debt Reasonably WellDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Mar 31Returns On Capital Are Showing Encouraging Signs At Corentec (KOSDAQ:104540)If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Is New 90 Day High Low • Feb 25New 90-day high: ₩18,800The company is up 50% from its price of ₩12,500 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩18,800, the stock is trading at a trailing P/E ratio of 69.8x, up from the previous P/E ratio of 58.1x. This compares to an average P/E of 18x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 50%.分析記事 • Feb 15Corentec Co., Ltd.'s (KOSDAQ:104540) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?Corentec (KOSDAQ:104540) has had a great run on the share market with its stock up by a significant 39% over the last...Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩16,600, the stock is trading at a trailing P/E ratio of 61.6x, up from the previous P/E ratio of 50.3x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 32%.Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩17,400, the stock is trading at a trailing P/E ratio of 64.6x, up from the previous P/E ratio of 53.5x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 26%.分析記事 • Dec 24Should You Use Corentec's (KOSDAQ:104540) Statutory Earnings To Analyse It?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...Is New 90 Day High Low • Dec 21New 90-day high: ₩15,150The company is up 66% from its price of ₩9,120 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,800, the stock is trading at a trailing P/E ratio of 39.3x, up from the previous P/E ratio of 33x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total return to shareholders over the past three years is a loss of 15%.Is New 90 Day High Low • Nov 10New 90-day high: ₩9,490The company is up 13% from its price of ₩8,400 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period.お知らせ • Nov 05Corentec Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Pureun Partners Asset ManagementCorentec Co., Ltd. (KOSDAQ:A104540) announced a private placement of 8th registered unsecured unguaranteed private convertible bonds for gross proceeds of KRW 15,000,000,000 on November 3, 2020. The bonds will not bear any interest and will have a yield to maturity of 0%. The bonds will mature on December 4, 2025. The bonds will be convertible into common shares at a fixed conversion price of KRW 8,900 per share between December 4, 2021 and November 4, 2025. The transaction has been approved by the board of the company. The payment date is December 4, 2020. The transaction will include participation from Pureun Partners Asset Management for KRW 15,000,000,000. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Corentec は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A104540 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026102,3772,95622,71226,404N/A12/31/2025100,4294,35522,86226,457N/A9/30/202598,0632,61922,78727,126N/A6/30/202592,09035515,58418,621N/A3/31/202589,179-5023,2286,191N/A12/31/202485,594-3,121-11,765-6,606N/A9/30/202489,419-3,814-12,734-6,861N/A6/30/202493,262-1,245-16,266-7,926N/A3/31/202491,9273,244-14,254-2,522N/A12/31/202392,0464,055-9,1932,634N/A9/30/202382,7792,786-8,7132,464N/A6/30/202376,0044,366-3,9736,516N/A3/31/202371,1532,125-3,7054,389N/A12/31/202263,9091,7813,90410,599N/A9/30/202256,3492,6476427,360N/A6/30/202249,646275-1,1975,912N/A3/31/202245,937335-2,2435,505N/A12/31/202144,630764-4,4814,076N/A9/30/202144,1591,869-5,1314,427N/A6/30/202142,8881,611-7,3811,476N/A3/31/202141,1661,585-10,534-1,407N/A12/31/202040,4961,574-10,303-3,608N/A9/30/202039,2372,843-8,280-126N/A6/30/202039,5642,885-7,326-1,928N/A3/31/202039,8393,288-3,1861,001N/A12/31/201940,1892,506N/A3,855N/A9/30/201935,277-26,722N/A3,893N/A6/30/201934,180-26,703N/A8,557N/A3/31/201934,510-28,647N/A8,062N/A12/31/201833,406-29,763N/A5,259N/A9/30/201836,247-9,552N/A3,523N/A6/30/201836,589-10,072N/A3,060N/A3/31/201836,568-8,734N/A5,538N/A12/31/201737,634-7,861N/A5,862N/A9/30/201738,243333N/A3,964N/A6/30/201737,683-66N/A2,986N/A3/31/201737,15779N/A913N/A12/31/201635,974466N/A2,942N/A9/30/201634,879169N/A3,567N/A6/30/201634,150349N/A3,663N/A3/31/201632,017-582N/A3,887N/A12/31/201530,347-859N/A2,545N/A9/30/201529,454-922N/A215N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A104540の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A104540の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A104540の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A104540の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A104540の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A104540の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/03 03:33終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Corentec Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Byung Hwa LeeShinhan Investment Corp.
分析記事 • Apr 01Shareholders Can Be Confident That Corentec's (KOSDAQ:104540) Earnings Are High QualityThe subdued stock price reaction suggests that Corentec Co., Ltd.'s ( KOSDAQ:104540 ) strong earnings didn't offer any...
お知らせ • Mar 13Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026Corentec Co., Ltd., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩5,490, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 19x in the Medical Equipment industry in South Korea. Total loss to shareholders of 50% over the past three years.
分析記事 • Dec 23There's No Escaping Corentec Co., Ltd.'s (KOSDAQ:104540) Muted Revenues Despite A 31% Share Price RiseCorentec Co., Ltd. ( KOSDAQ:104540 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩87.1b market cap, or US$59.2m).
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩6,810, the stock trades at a trailing P/E ratio of 58.8x. Average trailing P/E is 20x in the Medical Equipment industry in South Korea. Total loss to shareholders of 31% over the past three years.
分析記事 • Nov 05Investors Aren't Buying Corentec Co., Ltd.'s (KOSDAQ:104540) RevenuesCorentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a buy right now...
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩75.3b market cap, or US$54.2m).
分析記事 • Apr 10Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Mar 28New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩79.0b market cap, or US$53.9m).
お知らせ • Mar 13Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025Corentec Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 12, yeongsanhong 1-gil, ipjang-myeon, seobuk-gu, chungcheongnam-do, cheonan South Korea
分析記事 • Jan 06Lacklustre Performance Is Driving Corentec Co., Ltd.'s (KOSDAQ:104540) Low P/SCorentec Co., Ltd.'s ( KOSDAQ:104540 ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a buy right now...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩70.8b market cap, or US$49.3m).
Reported Earnings • Nov 20Third quarter 2024 earnings released: ₩70.00 loss per share (vs ₩113 profit in 3Q 2023)Third quarter 2024 results: ₩70.00 loss per share (down from ₩113 profit in 3Q 2023). Revenue: ₩22.0b (down 7.0% from 3Q 2023). Net loss: ₩897.3m (down 162% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
分析記事 • Nov 14Corentec's (KOSDAQ:104540) Returns On Capital Are Heading HigherWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
分析記事 • Sep 10Does Corentec (KOSDAQ:104540) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩6,350, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 62% over the past three years.
分析記事 • May 28Corentec Co., Ltd.'s (KOSDAQ:104540) Shares May Have Run Too Fast Too SoonWith a price-to-earnings (or "P/E") ratio of 35.4x Corentec Co., Ltd. ( KOSDAQ:104540 ) may be sending very bearish...
New Risk • May 25New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.6x net interest cover). Minor Risk Market cap is less than US$100m (₩107.4b market cap, or US$78.7m).
New Risk • Apr 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩132.0b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩132.0b market cap, or US$97.8m).
New Risk • Oct 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (3.3% increase in shares outstanding). Market cap is less than US$100m (₩135.1b market cap, or US$99.5m).
お知らせ • May 18Corentec Co., Ltd. announced that it has received KRW 1.19999236 billion in fundingOn May 17, 2023, Corentec Co., Ltd. closed the transaction.
お知らせ • May 11Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc.Corentec Co., Ltd. (KOSDAQ:A104540) acquired 80% stake in Woosung Pharma Inc. for KRW 7.2 billion on May 9, 2023. Corentec will acquire 92.34 million shares in Woosung Pharma. Corentec Co., Ltd. (KOSDAQ:A104540) completed the acquisition of 80% stake in Woosung Pharma Inc. on May 9, 2023.
お知らせ • May 10Corentec Co., Ltd. announced that it expects to receive KRW 1.19999236 billion in fundingCorentec Co., Ltd announced a private placement of 102,214 common shares of par value KRW 500 per share at an issue price of KRW 11,740 per share for gross proceeds of KRW 1,200,000,000 on May 9, 2023. The transaction will include participation from new investor Hwan-woo Cho. The company will issue securities through third party allotment method. All securities to be issued will be subject to a lock-up period of one year. The transaction has been approved by the board of directors of the company and is expected to close on May 17, 2023.
お知らせ • Feb 08Corentec Appoints Michael Son as Executive Vice PresidentCorentec has re-hired Michael Son to lead its sales and business development operations in the Americas, as Executive Vice President. Son will be responsible for pricing strategies, negotiations, hiring, and P&L, and will report to Corentec’s three Co-CEO’s, the Sun Brothers. Son, who was previously with Corentec from 2011 to 2015 as Vice President of Sales, brings more than 25 years of medical device sales experience where he worked with both large and small/start-up orthopedic companies in the European, Asia-pacific, U.S. and South America markets. Son is a highly strategic and influential medical device sales leader who will play an important role in building and strengthening relations between Corentec’s Korean operations and the Americas. Son holds a Bachelor of Arts Degree from University of Waterloo in Ontario, Canada, and is a graduate of the Executive Business Management program and National University of Singapore.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 17First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: ₩10.6b (up 6.7% from 1Q 2020). Net income: ₩953.1m (up 1.1% from 1Q 2020). Profit margin: 9.0% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
分析記事 • May 09These 4 Measures Indicate That Corentec (KOSDAQ:104540) Is Using Debt Reasonably WellDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Mar 31Returns On Capital Are Showing Encouraging Signs At Corentec (KOSDAQ:104540)If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...
Is New 90 Day High Low • Feb 25New 90-day high: ₩18,800The company is up 50% from its price of ₩12,500 on 27 November 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 25Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩18,800, the stock is trading at a trailing P/E ratio of 69.8x, up from the previous P/E ratio of 58.1x. This compares to an average P/E of 18x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 50%.
分析記事 • Feb 15Corentec Co., Ltd.'s (KOSDAQ:104540) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?Corentec (KOSDAQ:104540) has had a great run on the share market with its stock up by a significant 39% over the last...
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₩16,600, the stock is trading at a trailing P/E ratio of 61.6x, up from the previous P/E ratio of 50.3x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 32%.
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₩17,400, the stock is trading at a trailing P/E ratio of 64.6x, up from the previous P/E ratio of 53.5x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total returns to shareholders over the past three years are 26%.
分析記事 • Dec 24Should You Use Corentec's (KOSDAQ:104540) Statutory Earnings To Analyse It?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
Is New 90 Day High Low • Dec 21New 90-day high: ₩15,150The company is up 66% from its price of ₩9,120 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 2.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 19% share price gain to ₩10,800, the stock is trading at a trailing P/E ratio of 39.3x, up from the previous P/E ratio of 33x. This compares to an average P/E of 20x in the Medical Equipment industry in South Korea. Total return to shareholders over the past three years is a loss of 15%.
Is New 90 Day High Low • Nov 10New 90-day high: ₩9,490The company is up 13% from its price of ₩8,400 on 12 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period.
お知らせ • Nov 05Corentec Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Pureun Partners Asset ManagementCorentec Co., Ltd. (KOSDAQ:A104540) announced a private placement of 8th registered unsecured unguaranteed private convertible bonds for gross proceeds of KRW 15,000,000,000 on November 3, 2020. The bonds will not bear any interest and will have a yield to maturity of 0%. The bonds will mature on December 4, 2025. The bonds will be convertible into common shares at a fixed conversion price of KRW 8,900 per share between December 4, 2021 and November 4, 2025. The transaction has been approved by the board of the company. The payment date is December 4, 2020. The transaction will include participation from Pureun Partners Asset Management for KRW 15,000,000,000.